VMD Chief Medical Officer William Frazier Buys $18K of Stock
Viemed Healthcare's Chief Medical Officer, William Frazier, recently bought 10,000 shares valued at $18,100.
Reviewed by automated data checks against the source filing. How we make and check alerts
William Frazier, Chief Medical Officer at Viemed Healthcare, Inc. ($VMD), bought 10,000 shares at an average price of $1.81, worth about $18,100, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $VMD is up 2.8% after 1 week, up 3.7% after 1 month and down 18.9% to date (from the $11.69 close on Jun 25, 2026).
VMD
Viemed Healthcare, Inc.
Key Points
- William Frazier purchased 10,000 shares of Viemed Healthcare for $18,100 on June 25, 2026.
- The stock closed at $11.63 on the day of the transaction, reflecting a significant increase from its 52-week low of $6.05.
- Viemed Healthcare has a market cap of approximately $337 million and a P/E ratio of 24.6.
Get $VMD trade alerts by text
We text you when insiders, Congress or big funds trade $VMD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viemed Healthcare, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Viemed Healthcare, Inc.
William Frazier, the Chief Medical Officer of Viemed Healthcare, Inc. (NasdaqCM: VMD), bought 10,000 shares of the company on June 25, 2026, for a total value of $18,100. This purchase occurred at an average price of $1.81 per share. The transaction reflects Frazier's confidence in the company's prospects, especially following recent fluctuations in share ownership among insiders.
What Changed in Frazier's Holdings
Frazier's recent purchase adds to his previous transactions, where he sold 10,000 shares at a higher price of $11.72 earlier the same day. His stake in the company indicates a strategic move to manage his holdings amid recent trading activity.
Institutional Insights
No peer fund data is available for this report, but Viemed Healthcare continues to attract attention from analysts and insiders alike, suggesting a keen interest in its future performance.
How Viemed Healthcare, Inc. Stock Has Traded
Viemed Healthcare's shares traded at $11.63 on the day of Frazier's purchase. The stock has seen a notable rise from its 52-week low of $6.05, indicating positive momentum. Investors may take note of this upward trend as the company approaches its next earnings report scheduled for November 4, 2026.
Recent Earnings
Viemed Healthcare reported revenue of $301.6 million, marking a growth of 23.9%. The company has a net margin of 4.8% and an ROE of 10.5%. These earnings metrics reflect a solid performance, which could support the stock's upward trajectory.
Analysts Set New Price Targets
On August 24, 2026, Barrington Research initiated coverage on Viemed Healthcare with an "Outperform" rating and a price target of $14.00. Conversely, Freedom Broker downgraded the stock to a "Hold" rating with a target of $11.00 on August 6, 2026. The mixed ratings highlight varying opinions on the company’s future prospects.
What Viemed Healthcare, Inc. Does
Viemed Healthcare provides home medical equipment and respiratory healthcare services in the U.S. Its focus on treating chronic conditions like COPD underscores the importance of its products and services in the healthcare landscape. This insider purchase could signal a strong belief in the company's ongoing growth and market position.
What's Ahead for Viemed Healthcare, Inc.
Investors will be watching for Viemed's next earnings report on November 4, 2026, as it may provide further insights into the company's performance. Frazier's recent share purchase, along with the recent insider activity, suggests that there may be more developments to follow in the coming weeks.
Related Filing Alerts
Source: William Frazier's Form 4 filing on $VMD (Jun 25, 2026). Find the original filing: VMD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts